(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 December 2008 (18.12.2008)

PCT

(10) International Publication Number
WO 2008/154262 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 35/02* (2006.01)
A61K 9/16 (2006.01)

(21) International Application Number:
PCT/US2008/065838

(22) International Filing Date: 5 June 2008 (05.06.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07109816.4 7 June 2007 (07.06.2007) EP
60/974,197 21 September 2007 (21.09.2007) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GONCALVES, Elisabete** [PT/CH]; Friedrichstr. 13, CH-4055 Basel (CH). **KALB, Oskar** [DE/CH]; Oberwilerstrasse 88, CH-4054 Basel (CH). **MUTZ, Michael** [DE/DE]; Mozartstrasse 33, 79104 Freiburg (DE). **WIRTH, Wolfgang** [DE/CH]; Blauenrainstrasse 3b, CH-4422 Arisdorf (CH). **LAKSHMAN, Jay Parthiban** [US/US]; 169 Candlewick Lane, Bridgewater, New Jersey 08807 (US).

(74) Agent: **MANZARI, Oona A.**; Novartis, Patent Department, One Health Plaza Bldg. 104, East Hanover, New Jersey 07936-1080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

WO 2008/154262 A1

(54) Title: STABILIZED AMORPHOUS FORMS OF IMATINIB MESYLATE

(57) Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.